Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fish and Richardson
Baxter
Colorcon
Cipla
AstraZeneca
Fuji
Healthtrust
QuintilesIMS

Generated: April 20, 2018

DrugPatentWatch Database Preview

XELODA Drug Profile

« Back to Dashboard

When do Xeloda patents expire, and when can generic versions of Xeloda launch?

Xeloda is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in XELODA is capecitabine. There are twenty-eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Drug patent expirations by year for XELODA
Pharmacology for XELODA
Medical Subject Heading (MeSH) Categories for XELODA
Synonyms for XELODA
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
361C509
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine
6804DJ8Z9U
958887-39-3
AB0068959
AB01274776_04
AB01274776-01
AB01274776-02
AC1L1U83
AC1Q4KU8
AJ-45659
AK-72933
AKOS015920130
AM84502
Ambap154361-50-9
AMX10125
AN-16068
BC215614
BCP9000483
BCPP000300
BR-72933
BS-1000
C-20872
C12650
C15H22FN3O6
Capecitabin
capecitabina
CAPECITABINE
Capecitabine (Fluoropyrimidine)
Capecitabine (JAN/USAN/INN)
Capecitabine (Xeloda)
Capecitabine [USAN:USP:INN:BAN]
Capecitabine [USAN]
Capecitabine, >=98% (HPLC)
Capecitabine, analytical standard
Capecitabine, European Pharmacopoeia (EP) Reference Standard
Capecitabine, secondary pharmaceutical standard; traceable to USP, PhEur
Capecitabine, United States Pharmacopeia (USP) Reference Standard
capecitabinum
Capecitibine
Capecytabine
Capiibine
Captabin
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
CAS-154361-50-9
Caxeta
CC-25374
CC0143
CHEBI:31348
CHEMBL1773
CS-0768
CTK0H6126
CYT011
Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-
Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-
D00HCQ
D01223
DB01101
DR001889
DSSTox_CID_26451
DSSTox_GSID_46451
DSSTox_RID_81625
DTXSID3046451
EX-A835
FT-0082472
FT-0601618
FT-0696497
GAGWJHPBXLXJQN-UORFTKCHSA-N
GTPL6799
HSDB 7656
HY-B0016
J-700154
KS-00000E7O
LS-59070
MCULE-2851259722
MLS003915642
MLS004774137
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
n4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
NCGC00164569-01
NCGC00164569-02
NU000474
NU001808
NU006909
Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrim
Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-fluoro-2-oxo-pyrimidin-4-yl]carbamate
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate
PubChem21443
Q-200788
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978-000
Ro-09-1978/000
Ro-091978000
S-3173
s1156
SC-08810
SCHEMBL8153
SMR002530052
SR-01000931255
SR-01000931255-3
ST2413659
Tox21_112198
Tox21_112198_1
UNII-6804DJ8Z9U
Xabine
Xeloda (TN)
Xeloda, Captabin, Capecitabine
Z1741971721
ZINC3806413

US Patents and Regulatory Information for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ➤ Sign Up ➤ Sign Up
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ➤ Sign Up ➤ Sign Up
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ➤ Sign Up ➤ Sign Up
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for XELODA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 150 mg and 500 mg ➤ Subscribe 2008-11-10

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Deloitte
Colorcon
McKinsey
QuintilesIMS
Healthtrust
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.